Navigation Links
Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
Date:8/21/2008


Satisfies initial listing requirements with NASDAQ; Stock Symbol 'OGXI'

Implements immediate restructuring program, which extends cash runway

while focusing on clinical pipeline programs

BOTHELL, WA, Aug. 21 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (formerly Sonus Pharmaceuticals, Inc.) (NASDAQ: OGXI) (the "Company") announced that the Company has completed its acquisition of OncoGenex Technologies and NASDAQ has approved the commencement of trading in Company's common stock on The NASDAQ Capital Market under the stock symbol 'OGXI' effective today, August 21, 2008, when the market opens. Prior to completing the acquisition, the Company changed its name to OncoGenex Pharmaceuticals, amended its authorized share capital and effected a one-for-eighteen reverse stock split.

"Clearly the shareholders of both companies, Sonus Pharmaceuticals and OncoGenex Technologies, strongly favored this transaction and our efforts to maintain a NASDAQ listing," said Scott Cormack, President and Chief Executive Officer of OncoGenex Pharmaceuticals. "On August 19th, a very strong percentage of Sonus' shareholders voted in favor of the transaction and voted in favor of a reverse stock split. One hundred percent of OncoGenex Technologies' shareholders voted in favor of the transaction."

Additionally, as announced on August 20th, the Company has implemented cost-saving measures to preserve cash while focusing on its highest potential product development programs. The Company will reduce workforce by approximately 49%. As a result of these actions, the Company will incur approximately $1.2 million in charges in the third quarter of 2008, associated with employee severance costs. Management estimates that
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
2. Sonus Pharmaceuticals Receives Favorable NASDAQ Decision
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... company focused on the development of autologous cell ... Phase 1/2 clinical trial of RCT-01, being tested ... has been enrolled and their tissue biopsy sent ... is comprised of non-bulbar dermal sheath (NBDS) cells ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... 14. She has accepted the position of vice president of instruction at Chippewa ... , “I greatly appreciated the opportunity to lead SIUE during the past ...
(Date:6/30/2015)... ... June 30, 2015 , ... Cannavoices , ... an unprecedented digital video and broadcast initiative. Produced by filmmakers, the multi-platform initiative ... of legal medical cannabis stories ever assembled. , Cannavoices profiles Advocates, Patients, ...
(Date:6/29/2015)... 2015   Pharnext SAS today announced that data ... treatment of Charcot-Marie-Tooth Type 1A (CMT1A), is being presented in ... Nerve Society (PNS) Biennial Meeting at the Quebec Congress Center ... - July 2, 2015. At Poster Viewing Session ... 5p.m. to 7p.m. EDT: Poster 23: "A ...
Breaking Biology Technology:RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting 2
... PharmAthene, Inc.,(Amex: PIP ) a biodefense ... announced that the Delaware Chancery Court,today issued a ... dismiss,PharmAthene,s complaint, which alleges that it has a ... SIGA,s drug candidate, SIGA-246. SIGA,s,request to dismiss the ...
... Helix BioPharma Corp.,(TSX: HBP/Frankfurt: WKN 918846) announced today ... Inc. ("KBI") to develop a process for,preparing L-DOS47 ... clinical testing., "This new arrangement advances the ... with L-DOS47," said John Docherty, Helix,s,president. "The lyophilized ...
... Bristol-Myers Squibb,Company (NYSE: BMY ) will announce ... on Thursday, January 31. During a 10 a.m. (ET) ... information and will,address inquiries from investors and analysts., ... to a live,webcast of the call at http://www.bms.com/ir ...
Cached Biology Technology:Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthene's Legal Action in Breach of Contract Lawsuit Against SIGA 2Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format 2Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format 3
(Date:6/10/2015)... June 10, 2015 According ... Market by Technology (Ultrasound, TOF, Structured Light, Stereo ... Entertainment, Automotive) and by Geography - Trends & ... the market is expected to reach $3,319.71 Million ... between 2015 and 2020. Browse 71 ...
(Date:6/9/2015)... DUBLIN , June 09, 2015 ... the addition of the "Gesture Recognition & ... Application (Consumer Electronics, Automotive, & Others), Product (Biometric ... Forecast to 2020" report to their offering. ... sensing market is expected to reach $ 23.55 ...
(Date:6/8/2015)... 2015  The Secure Identity & Biometrics ... Troy Potter of L-3 National Security ... a non-profit association that was established in February ... implementation of solutions that protect and secure identity ... Photo - ...
Breaking Biology News(10 mins):3D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 3Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 4Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 5
... Researchers at Washington University in St. Louis have figured ... complex to its neighboring membrane in a photosynthetic bacterium, ... in photosynthesis. Robert Blankenship, Ph.D., Markey Distinguished Professor ... a team that for the first time combined chemical ...
... -- Three leading research centers based in Woods Hole, ... a new alliance that will bring their combined scientific ... facing society today and spawn scientific growth and job ... consortium comprises the Woods Hole Marine Biological Laboratory (MBL), ...
... that appears to prevent some men from conceiving children ... according to University of Iowa researchers reporting their findings ... American Journal of Human Genetics . Although female ... have proven very effective for family planning, no similar ...
Cached Biology News:Orientation of antenna protein in photosynthetic bacteria described 2Orientation of antenna protein in photosynthetic bacteria described 33 Woods Hole scientific institutions forge alliance to address societal issues 23 Woods Hole scientific institutions forge alliance to address societal issues 3Gene discovery could lead to male contraceptive 2
Request Info...
Bovine Serum Albumin Heat Shock Diagnostic Grade Powder...
... provides the premium quality siRNAs you need ... can be readily ordered online by providing ... by providing the sense and antisense siRNA ... Validated and Silencer Pre-designed ...
... siRNA service provides the premium quality siRNAs ... Custom siRNAs can be readily ordered online ... sequence, or by providing the sense and ... Silencer Validated and Silencer ...
Biology Products: